- Telix Pharma projects its 2025 revenue to be between $770 million and $800 million.
- The company’s net income for 2024 significantly increased to A$49.9 million from A$5.2 million in the previous year.
- There was no change in the final dividend per share, remaining at A$0.0 year-over-year.
- Revenue from contracts with customers rose by 56% to A$783.2 million compared to the previous year.
- The gross margin improved to 65% from last year’s 63%.
- Telix Pharma’s cash balance grew substantially to A$710.3 million from A$123.2 million.
- The company plans to increase its R&D expenditure by 20% to 25% in FY2025 compared to FY2024.
- Telix finalized the acquisition of RLS, a radiopharmacy network, on January 28, 2025; however, RLS’s financial results will be reported starting in 2025.
- Analyst recommendations include 8 buys, 1 hold, and 1 sell for Telix Pharma.
Telix Pharmaceuticals on Smartkarma
Analyst coverage on Telix Pharmaceuticals on Smartkarma shows a mix of bullish sentiments from top independent analysts. Brian Freitas highlights Telix’s unexpected inclusion in the VanEck Vectors Australian Equal Weight ETF in December, with changes leading to a significant round-trip trade of A$290m. Travis Lundy points out Telix as an ADD for the December 2024 review, expecting a one-way flow of $US90mm. Tina Banerjee discusses Telix’s Phase 3 trials and new product launches, emphasizing the favorable payment rule in the US for specialized radiopharmaceuticals, which could benefit Telix.
Overall, the analysts’ reports on Telix Pharmaceuticals suggest a positive outlook with growth drivers such as the Phase 3 trials, revenue growth, and market expansion. Investors may find these insights valuable in assessing Telix’s potential in the pharmaceutical sector and its position in the market.
A look at Telix Pharmaceuticals Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 5 | |
| Resilience | 5 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, Telix Pharmaceuticals has a promising long-term outlook. With strong scores in Growth, Resilience, and Momentum, the company seems well-positioned for future success. Telix Pharmaceuticals is focused on developing and commercializing molecularly-targeted radiation therapy for various types of cancer, indicating a commitment to innovation and addressing critical healthcare needs. Their high scores in Growth, Resilience, and Momentum suggest a company with significant potential for expansion, stability, and market traction.
Although Telix Pharmaceuticals scored lower in terms of Value and Dividend, the high scores in Growth, Resilience, and Momentum indicate a company that is prioritizing innovation and growth over immediate returns to shareholders. This approach could pay off in the long term as the company continues to develop cutting-edge therapies for cancer treatment. Investors looking for a company with a strong growth trajectory and a focus on resilience and momentum may find Telix Pharmaceuticals to be an appealing long-term investment option.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
